2023
DOI: 10.1093/nar/gkad862
|View full text |Cite
|
Sign up to set email alerts
|

TheMarker: a comprehensive database of therapeutic biomarkers

Yintao Zhang,
Ying Zhou,
Yuan Zhou
et al.

Abstract: Distinct from the traditional diagnostic/prognostic biomarker (adopted as the indicator of disease state/process), the therapeutic biomarker (ThMAR) has emerged to be very crucial in the clinical development and clinical practice of all therapies. There are five types of ThMAR that have been found to play indispensable roles in various stages of drug discovery, such as: Pharmacodynamic Biomarker essential for guaranteeing the pharmacological effects of a therapy, Safety Biomarker critical for assessing the ext… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 29 publications
(2 citation statements)
references
References 93 publications
0
1
0
Order By: Relevance
“…Furthermore, the upcoming version of CyclicPepedia will predominantly focus on the data regarding cyclic peptide targets and their pharmacology properties. Pharmaceutical databases such as the Therapeutic Target Database [ 47 ], VARIDT [ 48 ], INTEDE [ 49 ], Comparative Toxicogenomics Database [ 50 ], TheMarker [ 51 ], and DrugMAP [ 52 ] will be explored for molecular interactions of cyclic peptides. Simultaneously, efforts will be made to enhance data quality and accuracy control, preventing the inclusion of duplicate or erroneous data.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, the upcoming version of CyclicPepedia will predominantly focus on the data regarding cyclic peptide targets and their pharmacology properties. Pharmaceutical databases such as the Therapeutic Target Database [ 47 ], VARIDT [ 48 ], INTEDE [ 49 ], Comparative Toxicogenomics Database [ 50 ], TheMarker [ 51 ], and DrugMAP [ 52 ] will be explored for molecular interactions of cyclic peptides. Simultaneously, efforts will be made to enhance data quality and accuracy control, preventing the inclusion of duplicate or erroneous data.…”
Section: Discussionmentioning
confidence: 99%
“…In addition to treatment efficacy, drug safety is also vital in the individualisation of therapy. Certain biomarkers can be used to evaluate drug toxicity [95]. Taking hepatotoxicity as an example, biomarkers such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and other liver function tests are used to detect hepatotoxicity.…”
mentioning
confidence: 99%